Frequency of Change in Assessment from Bony Union to Nonunion after Lumbar Interbody Fusion: A Multicenter Study

Hiroki Oba¹, Jun Takahashi¹, Yosuke Shibata⁵, Tetsuro Ohba⁹, Tomohiko Hasegawa⁶, Yukihiro Isogai⁷, Shugo Kuraishi¹, Shota Ikegami¹, Masashi Uehara¹, Takashi Takizawa¹, Ryo Munakata¹, Terue Hatakenaka¹, Toshiyuki Ojima¹, Zentaro Yamagata⁶, Yukihiro Matsuyama⁴ and Hirotaka Haro³

1) Department of Orthopaedic Surgery, Shinshu University, School of Medicine, Matsumoto, Japan
2) Departments of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
3) Department of Orthopaedic Surgery, University of Yamanashi, School of Medicine, Chuo, Japan
4) Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
5) Medical Affairs Department, Pharmaceutical Business Administration Division, Asahi Kasei Pharma Corporation, Tokyo, Japan
6) Departments of Health Science for Clinical Medicine, Graduate School of Medicine, University of Yamanashi, Chuo, Japan

Abstract:

Introduction: Assessments of early postoperative bony union after posterior lumbar interbody fusion via computed tomography (CT) have revealed cases in which interbody fixation by bony union resulted in nonfusion due to bone absorption. The apparent bone union state reverted to a nonunion state several months later, exhibiting a so-called “fake union” phenomenon. Additionally, few reports have evaluated the effect of teriparatide on bony union. The present study aimed to evaluate the frequency of change in assessment from fusion to nonfusion in the postoperative follow-up of lumbar interbody fusion, compare the late postoperative bony union rates in groups with or without early postoperative fusion, and examine the effect of postoperative teriparatide in those groups.

Methods: Sixty-nine subjects enrolled from multiple hospitals were prospectively evaluated following single-level lumbar interbody fusion. The patients were randomly allocated into treatment with or without weekly postoperative teriparatide. The subjects were then classified as having bony union or nonfusion at 2 months postoperatively, and fusion rates at 6 months were compared. For the evaluation of bony union, blinded radiological examinations were performed via CT. Additional comparisons were made according to teriparatide use.

Results: The rate of nonunion at 6 months postoperatively in patients with fusion at 2 months postoperatively was 27.8%. Among subjects with bony union at 2 months postoperatively, the fusion rate at 6 months in those who received teriparatide was 93.3% (p=0.027) versus 57.1% in those who did not.

Conclusions: The rate of nonunion at 6 months postoperatively in patients exhibiting union at 2 months after surgery was 27.8%. Postoperative weekly teriparatide treatment significantly reduced the rate of fake union.

Keywords:
posterior lumbar interbody fusion, transforaminal lumbar interbody fusion, bony union, delayed fusion, bone resorption, weekly teriparatide

Introduction

The rapid progression of societal aging has been accompanied by an increase in lumbar degenerative disease⁷. Posterior (PLIF) or transforaminal lumbar interbody fusion (TLIF) is usually conducted to treat lumbar degenerative...
Figure 1. Sagittal and coronal CT of L4/5 PLIF in a 70-year-old woman. Panels A and B: 2 months postoperatively; C and D: 4 months postoperatively; E and F: 6 months postoperatively. Bony union at 2 and 4 months was reassessed as nonfusion at 6 months.

disease in the elderly, although these procedures sometimes fail to achieve bony union. If bone union is not attained after the initial operation, failure rates as high as 40%-70% have been reported for repeat fusion surgery because of the development of pseudarthrosis.

In some cases, patients assessed as having early postoperative bony union are subsequently diagnosed as having nonfusion, or a so-called "fake union," several months later. We defined fake union as the phenomenon of bone continuity observed via computed tomography (CT) at 2 months after surgery but not at 6 months after surgery. This process is likely the result of bone absorption that is detectable on CT (Fig. 1). To the best of our knowledge, no reports have addressed the frequency or prevention of fake union.

The present study evaluated bony union at 2, 4, and 6 months after surgery in 69 subjects who underwent single-level interbody fusion to determine 1) the frequency of fake union; 2) the relationship between the presence/absence of bony union at 2 or 4 months postoperatively and fusion at 6 months postoperatively, as well as the effect of weekly teriparatide on the fake union in subjects assessed as having fusion at 2 or 4 months postoperatively; and 3) the factors associated with bony union at 2, 4, and 6 months after surgery.

**Materials and Methods**

**Patients and study measures**

This was an additional analysis using data obtained by a prior multicenter, prospective, randomized trial to investigate the impact of weekly teriparatide administration on bony union enhancement after PLIF or TLIF for osteoporosis-associated lumbar degenerative disease during the early postoperative period. Patient consent for additional research was obtained in the previous study. The subjects were enrolled from among three university hospitals and their affiliates. The patients were all women aged >50 years having a bone mineral density/young adult mean ratio of < 80% and/or previous spinal compression and/or hip fracture, as well as a lumbar degenerative disease. Single-level PLIF or TLIF was applied to treat lumbar spinal stenosis, degenerative spondylolisthesis, and isthmic spondylolisthesis. Multilevel decompression was performed when necessary, and these cases were included in the study. All subjects were treated using posterior instrumentation with pedicle screws.
Posterolateral fusion was not conducted. Interbody spaces were filled by a box cage of polyetheretherketone filled with local bone. Residual bone was discarded. After receiving informed patient consent, we registered each case with an independent central office, which randomly assigned the subjects into treatment groups of either teriparatide once weekly administered subcutaneously starting at week 1 for 6 months postoperatively or no teriparatide treatment. Postoperatively, all patients commenced 1.2 g/day calcium l-aspartate after 1 week as a basic treatment for osteoporosis, wore a soft lumbar corset for 3 months, and performed standardized physical training that included exercises to strengthen back muscles and improve walking.

**Evaluation method for bony union**

Bony union was assessed by CT and dynamic X-rays at 2, 4, and 6 months postoperatively by four physicians who were blinded to the results using a fusion grading system described by Bridwell\(^1\). Two CT slices at the center of the cage in both the coronal and sagittal views were used to evaluate bone healing. Each evaluation was conducted by four clinicians (two clinicians each from two universities excluding the university at which the surgery was performed) using CT images. During the initial evaluation, a consensus was achieved after the agreement of ≥3 evaluators. If ≤2 evaluators agreed, further evaluation was performed until a unanimous decision.

**Radiological assessment**

Subjects were classified into either the fusion or nonfusion groups at 2 and 4 months postoperatively, and the fusion rate in each group was determined at 6 months postoperatively. Additional analyses were conducted according to the use/nonuse of postoperative weekly teriparatide. Baseline characteristics, surgical method and levels, and teriparatide administration after surgery were compared between the fusion and nonfusion groups at 2, 4, and 6 months postoperatively. We also examined for parameters related to bony union at those time points.

**Statistical analysis**

Analyses were conducted using Fisher’s exact test for categorical data and Student’s *t*-test for continuous data. Bony union scores were analyzed using analysis of covariance and adjusted for age as a covariate. For all analyses, the level of significance was set at *p*<0.05. Statistical testing was conducted independently by three academic medical statisticians. All analyses were performed using SPSS Statistics 24 for Windows (SPSS Inc., Chicago, Illinois, USA).

**Results**

**Overall data**

A total of 69 subjects (all female, mean age at surgery: 71.5 years) who completed the evaluation of bony union using dynamic X-rays and three-dimensional CT at 2, 4, and 6 months postoperatively were enrolled. Surgery was performed for degenerative spondylolisthesis in 54 subjects, degenerative scoliosis in two subjects, spinal stenosis in 10 subjects, and isthmic spondylolisthesis in three subjects. Six subjects received osteoporosis treatment before surgery. Table 1 shows the baseline characteristics. PLIF was conducted in 65 patients and TLIF in four patients. No significant post-

---

**Table 1.** Characteristics of Patients at Baseline (N=69).

| Socio-demographic factor | Value                  |
|--------------------------|------------------------|
| Age (y)                  | 71.1±7.5 (56–88)\(^1\) |
| Sex                      | Male 0, Female 69      |
| Height (cm)              | 149.3±6.5 (131.0–162.5)\(^1\) |
| Weight (kg)              | 51.8±7.9 (37.7–70.6)\(^1\) |
| Disease                  | Degenerative spondylolisthesis 54 (78%) |
|                          | Degenerative scoliosis 2 (3%) |
|                          | Spinal stenosis 10 (14%) |
|                          | Isthmic spondylolisthesis 3 (4%) |
| Pretreatment of osteoporosis | – 64 (93%), + 5 (7%) |
| Femoral BMD (%YAM)       | Femoral neck 0.75±0.10 (0.47–0.93)\(^1\) |
|                          | Total proximal 0.79±0.11 (0.51–1.07)\(^1\) |
| Femoral BMD (T-score)    | Femoral neck –2.28±0.83 (−4.64–0.62)\(^1\) |
|                          | Total proximal –1.90±1.00 (−4.58–0.49)\(^1\) |
| Serum P1NP (µg/L)        | 45.1±18.8 (13.2–95.4)\(^1\) |
| Serum TRACP-5b (mU/dL)   | 455±180 (128–1010)\(^1\) |

\(^1\)Numbers in parentheses are minimum–maximum values. Plus-minus values represent the mean±standard deviation.

Abbreviations: BMD, bone mineral density; YAM, young adult mean; P1NP, N-terminal cross-linking propeptide of type 1 procollagen; TRACP-5b, tartrate-resistant acid phosphatase-5b
operative complications, such as epidural hematoma or surgical site infection, were recorded. Postoperative weekly teriparatide was administered to 36 subjects. The overall bony union rates at 2, 4, and 6 months postoperatively were 51%, 50%, and 46%, respectively (Table 2).

Table 2. Surgical Techniques and Outcomes (N=69).

| Surgical technique | N (%)       |
|--------------------|-------------|
| PLIF               | 65 (94%)    |
| TLIF               | 4 (6%)      |
| Level              |             |
| L3-4               | 4 (6%)      |
| L4-5               | 58 (84%)    |
| L5-S1              | 7 (10%)     |
| Complications of surgery |         |
| Dural tears        | 0           |
| Epidural hematoma  | 0           |
| Surgical site infection |    0       |
| Postoperative teriparatide |    |
| Used               | 31 (45%)    |
| Not used           | 38 (55%)    |
| Bony union         |             |
| 2 months postoperatively | 36 (52%)  |
| 4 months postoperatively | 37 (54%)  |
| 6 months postoperatively | 34 (49%)  |
| Screw loosening    |             |
| 2 months postoperatively | 0 (0%)    |
| 4 months postoperatively | 2 (3%)    |
| 6 months postoperatively | 3 (4%)    |

Abbreviations: PLIF, posterior lumbar interbody fusion; TLIF, transforaminal lumbar interbody fusion
Bony union was judged as achieved when the central slice in CT imaging of both coronal and sagittal sections revealed bony union. Bony union was judged as absent when either central slice showed nonfusion.

Rate of fake union

In patients with fusion at 2 and 4 months postoperatively, 72.2% and 73.0%, respectively, also achieved fusion at 6 months (Table 3). Accordingly, the respective rates of fake union in subjects with fusion at 2 and 4 months were 27.8% and 27.0%. Among the patients in the fusion (36 subjects) and nonfusion groups (33 subjects) at 2 months postoperatively, the fusion rates at 6 months were 72.2% and 24.2%, respectively. Therefore, subjects with fusion at 2 months postoperatively were more likely to achieve fusion at 6 months.

Impact of postoperative weekly teriparatide

Table 4 summarizes the additional analysis of fusion rates according to use/nonuse of postoperative weekly teriparatide. Patients receiving weekly teriparatide were more likely to maintain fusion. Of the 36 subjects who achieved fusion at 2 months after surgery, 15 subjects used teriparatide and 21 subjects did not. The numbers of patients achieving bony union with and without teriparatide at 6 months postoperatively were 14 (93.3%) and 12 (57.1%), respectively. Accordingly, the respective rates of fake union in the teriparatide use and nonuse groups were 6.7% and 42.9%.

Predictors of bony union at 2, 4, and 6 months postoperatively

Table 5 shows the associations between predictive factors and bony union at 2, 4, and 6 months postoperatively. The procedure performed (TLIF or PLIF) was not a significant predictor of bony union. The bony union rates including and excluding L5/S were comparable at 57.1% and 48.4%, respectively. The use of weekly teriparatide was not remarkably associated with bony union at 2 or 4 months postoperatively but was significantly related to fusion at 6 months after surgery (p=0.022) (Fig. 2).

Discussion

This study made three important clinical observations regarding bony union after TLIF or PLIF: First, early (2 and 4 months) postoperative bony union was reassessed as nonfusion at 6 months, i.e., fake union, at an unexpectedly high frequency. Second, subjects judged as achieving early postoperative fusion showed higher bony union rates at the final evaluation than did those who did not attain early fusion. Third, although the use of weekly teriparatide was not notably related to bony union at 2 or 4 months postoperatively, it was significantly associated with bony union at 6 months (p=0.022).

Among the subjects assessed as having bony union at 2 months postoperatively, 27.8% were later reassessed as having nonfusion at the final evaluation. More alarmingly, 27.0% of subjects classified as having fusion at 4 months postoperatively were reclassified as having nonfusion at the final time point. We routinely perform follow-up to detect implant failure or screw back-out and determine the need for trunk orthosis until bony union. This study revealed that over a quarter of subjects with fusion at 4 months postoperatively might have had fake union. Hence, patients should be advised of a possibility of nonunion, and careful follow-up and lifestyle guidance should be continued.

In subjects with bony union at 2 months postoperatively, 72.2% maintained fusion at the final evaluation, whereas only 24.2% of patients with nonfusion at 2 months could achieve fusion at 6 months. Early postoperative CT can predict the likelihood of bony union at the final evaluation and provide the meaningful information needed to establish a treatment plan. However, early postoperative CT images appearing to show bony union may be misread, which instead represents curettage of endplate cartilage or dense bonegrafting with the actual bony union not yet present. Fake union is presumed to be a failure of a biological bony union as a result of the resorption of the impacted bone graft. Cho et al. performed PLIF on 47 patients with osteoporosis...
and evaluated bony union with or without weekly teriparatide use at 24 months postoperatively using Ito’s classification. The 6 month postoperative fusion rates with and without teriparatide were 77.8% and 53.6%, respectively. In our cohort, the fusion rates at 6 months postoperatively with and without weekly teriparatide use were lower at 58.8% and 41.2%, respectively. This finding might be attributed to a different evaluation method used in our study, with the fusion grading system by Bridwell being stricter than that of Ito. The overall fusion rate in our study was also lower than that in previous studies, possibly because of the involvement of four evaluators, as described previously. Moreover, the inclusion of women aged ≥50 years in our study population might have decreased the bony union rate.

Teriparatide use was not related to bony union at 2 or 4 months postoperatively but was significantly related to fusion at 6 months (p=0.022). Among the subjects assessed as having bony union at 2 months postoperatively, 6.7% who received weekly teriparatide in fact had fake union, whereas 42.9% of those who did not take the drug had fake union. Hence, teriparatide use was associated with a significantly lower fake union rate (p=0.024). No other factors were found to be related to bony union at 2 months postoperatively, suggesting that the occurrence of fusion at that time was related more to the quality of bone graft surgery and less to patient status. Weekly teriparatide administration may promote osteogenesis and increase fusion rates at 6 months. Bone absorption leading to fake union in the early stages (approximately 2-6 months) is typically followed by bone union; teriparatide may help mitigate these initial symptoms. Accordingly, we recommend at least 6 months of continuous weekly teriparatide in women with lower bone density.

Several studies have examined pseudarthrosis and methods to reduce its incidence, one of which is the use of teriparatide. Ohtori et al. prospectively analyzed bony union rates after posterolateral lumbar fusion with local bone grafting in patients postoperatively treated with daily subcutaneous injections of 20 μg of teriparatide and revealed a fusion rate of 82% in the teriparatide group and 68% in the oral bisphosphonate group. Similarly, in 2016, our team described that combined lumbar interbody fusion and weekly teriparatide administration could be an option for the management of lumbar degenerative disease in the elderly since the drug was effective in reducing pseudarthrosis.

### Table 3. Relationship Between Bony Union at 2 and 4 Months Postoperatively and Bony Union at 6 Months Postoperatively.

|          | 2 months |          |          | 4 months |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|          | Fusion   | Nonfusion | p        | Fusion   | Nonfusion | p        | Fusion   | Nonfusion | p        |
| 6 months | 26       | 8        | 24.2%    | <0.001   | 27       | 7         | 73.0%    | 21.9%    | <0.001   |
| Fusion   | 10       | 25       | 75.8%    | 10       | 25       | 78.1%    |          |          |          |
| Total    | 36       | 33       | 100.0%   | 37       | 32       | 100.0%   |          |          |          |

A p-value of <0.05 was defined as statistically significant.

### Table 4. Relationship Between Bony Union at 2 Months Postoperatively and Bony Union at 4 or 6 Months Postoperatively According to Weekly Teriparatide Use.

#### 2 months fusion group (n=36)

|          | 4 months |          |          | 6 months |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|          | Teriparatide (−) | Teriparatide (+) | p | Teriparatide (−) | Teriparatide (+) | p | Teriparatide (−) | Teriparatide (+) | p |
| Fusion   | 14       | 14       | 93.3%    | 0.104    | 12       | 14       | 93.3%    | 0.024†   |
| Nonfusion| 7        | 1        | 6.7%     |          | 9        | 1        | 6.7%     |          |
| Total    | 21       | 15       | 100.0%   | 21       | 15       | 100.0%   |          |          |

#### 2 months nonfusion group (n=33)

|          | 4 months |          |          | 6 months |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|          | Teriparatide (−) | Teriparatide (+) | p | Teriparatide (−) | Teriparatide (+) | p | Teriparatide (−) | Teriparatide (+) | p |
| Fusion   | 3        | 6        | 37.5%    | 0.259    | 2        | 6        | 37.5%    | 0.118    |
| Nonfusion| 14       | 10       | 62.5%    | 15       | 10       | 62.5%    |          |          |
| Total    | 17       | 16       | 100.0%   | 17       | 16       | 100.0%   |          |          |

Teriparatide (−) represents the nonuse of weekly teriparatide.
Teriparatide (+) represents the use of weekly teriparatide.
A p-value of <0.05 was defined as statistically significant.
†Indicates statistical significance.
Table 5. Predictors of Bony Union at 2, 4, and 6 Months Postoperatively.

|                        | Bony union at 2 months | Bony union at 4 months | Bony union at 6 months |
|------------------------|------------------------|------------------------|------------------------|
|                        | Nonfusion | Fusion | p    | Nonfusion | Fusion | p    | Nonfusion | Fusion | p    |
| Frailty fracture       | (−)       | 28     | 84.8%| 31     | 86.1% | 0.999| 28       | 87.5% | 31     | 83.8% | 0.742| 30       | 85.7% | 29     | 85.3% | 1.000 |
|                        | (+)        | 5      | 15.2%| 5      | 13.9% |          | 4        | 12.5% | 6      | 16.2% |          | 5      | 14.3% | 5      | 14.7% |
| Level                  | L3-4       | 1      | 3.0% | 3      | 8.3% | 0.246| 1        | 3.1%  | 3      | 8.1%  | 0.652| 1        | 2.9%  | 3      | 8.8%  | 0.495 |
|                        | L4-5       | 27     | 81.2%| 31     | 86.1% |          | 28       | 87.5% | 30     | 81.1% |          | 31     | 88.6% | 27     | 79.4% |
|                        | L5-S1      | 5      | 15.2%| 2      | 5.6%  |          | 3        | 9.4%  | 4      | 10.8% |          | 3      | 8.6%  | 4      | 11.8% |
| Surgical treatment     | PLIF       | 30     | 90.9%| 35     | 97.2% | 0.343| 30       | 93.8% | 35     | 94.6% | 1.000| 32       | 91.4% | 33     | 97.1% | 0.614 |
|                        | TLIF       | 3      | 9.1% | 1      | 2.8%  |          | 2        | 6.3%  | 2      | 5.4%  |          | 3      | 8.6%  | 1      | 2.9%  |
| Weekly teriparatide    | (−)        | 17     | 51.5%| 21     | 58.3% | 0.633| 21       | 65.6% | 17     | 45.9% | 0.101| 24       | 68.6% | 14     | 41.2% | 0.022^ |
|                        | (+)        | 16     | 48.5%| 15     | 41.7% |          | 11       | 34.4% | 20     | 54.1% |          | 11     | 31.4% | 20     | 58.8% |
| Pretreatment of osteoporosis | (−) | 29     | 87.9%| 35     | 97.2% | 0.186| 30       | 93.8% | 34     | 91.9% | 1.000| 32       | 91.4% | 34     | 94.1% | 1.000 |
|                        | (+)        | 4      | 12.1%| 1      | 2.8%  |          | 2        | 6.3%  | 3      | 8.1%  |          | 3      | 8.6%  | 2      | 5.9%  |
| Hypertension           | (−)        | 23     | 69.7%| 23     | 63.9% | 0.799| 21       | 67.7% | 24     | 64.9% | 0.803| 22       | 64.7% | 23     | 67.6% | 0.798 |
|                        | (+)        | 10     | 30.3%| 13     | 36.1% |          | 10       | 32.3% | 13     | 35.1% |          | 12     | 35.3% | 11     | 32.4% |
| Diabetes               | (−)        | 30     | 90.9%| 32     | 88.9% | 0.999| 27       | 87.1% | 34     | 91.9% | 0.694| 31       | 91.2% | 30     | 88.2% | 1.000 |
|                        | (+)        | 3      | 9.1% | 4      | 11.1% |          | 4        | 12.9% | 3      | 8.1%  |          | 3      | 8.8%  | 4      | 11.8% |
| Malignant neoplasm     | (−)        | 33     | 100.0%|33     | 91.7% | 0.240| 30       | 96.8% | 35     | 94.6% | 1.000| 33       | 97.1% | 32     | 94.1% | 1.000 |
|                        | (+)        | 0      | 0.0% | 3      | 8.3%  |          | 1        | 3.2%  | 2      | 5.4%  |          | 1      | 2.9%  | 2      | 5.9%  |

Abbreviations: (−), absence of symptom; (+), presence of symptom; PLIF, posterior lumbar interbody fusion; TLIF, transforaminal lumbar interbody fusion
A p-value of <0.05 was defined as statistically significant.
^Indicates statistical significance.

Figure 2. Differences in bony union rates with postoperative teriparatide.
Teriparatide use was not remarkably related to fusion at 2 or 4 months but was significantly associated with fusion at 6 months (p=0.022).
Abbreviation: M: months
A p-value of <0.05 was defined as statistically significant.
*Statistically significant.

Lastly, pseudarthrosis may still occur despite various preventive measures, including those discussed above. The failure rate of repeat surgery for pseudarthrosis correction is 40%–70%. CT is mandatory to evaluate bony union. However, some reports have suggested a relationship between increased X-ray exposure and cancer development and recommended less frequent CT imaging. We propose performing CT at two time points: once in the early postoperative period to assess implant position, bony decompression, and early fusion and a second time at 6 months after surgery to evaluate bony union. This study has several limitations. First, the follow-up period was relatively short. Although the natural course of this type of treatment includes initial absorption of implanted bone, teriparatide may prevent absorption and promote earlier bony union. In previous reports on bony union rate after intervertebral fusion, Cho et al. reported fusion within 6.0 months, and Ebara et al. performed their final evaluation for bony union at 6 months after surgery. However, the definitive diagnosis of pseudarthrosis requires at least 12 months of follow-up. Second, this study assessed bony union with CT, which might have misinterpreted bone surfaces in contact with each other as bony union. Since a conclusive assessment of bony union cannot be performed solely using CT, other modalities, including dynamic CT, magnetic resonance imaging, positron emission tomography, contrast radiography, and bone scintigraphy, should be considered to improve diagnostic precision. Third, the subjects in this study were limited to women aged 50 years with osteoporosis who underwent single-vertebral PLIF or TLIF (Table 6). The same results may also be expected for multilevel fusion, oblique lumbar interbody fusion, and extreme lateral interbody fusion; additional research of those groups is necessary. Fourth, this study did not analyze the effects of cage type or smoking, both of which could have affected nonun-
Table 6. Comparison of Preoperative Bone Metabolism Markers in the Bony Union Group and Non-bony Union Group.

| Bony union at 6 months postoperatively | Nonfusion (n=35) | Fusion (n=34) | p    |
|---------------------------------------|-----------------|--------------|------|
| BMD of femoral neck (%YAM)            | 0.73±0.10       | 0.74±0.10    | 0.810|
| BMD of total proximal femur (%YAM)    | 0.79±0.10       | 0.79±0.12    | 0.953|
| PINP (μg/L)                           | 48.2±19.7       | 41.9±17.7    | 0.195|
| TRACP-5b (μU/dL)                      | 493±212         | 415±134      | 0.088|

Abbreviations: BMD, bone mineral density; PINP, N-terminal cross-linking propeptide of type 1 procollagen; TRACP-5b, tartrate-resistant acid phosphatase-5b

Pluses and minuses represent the mean±standard deviation.

A p-value of <0.05 was defined as statistically significant.

ion rates. Lastly, the number of subjects in this study was relatively small.

Conclusion

Subjects assessed as having an early postoperative bony union at 2 months tended to achieve fusion at the final evaluation at 6 months more frequently than those without bony union at an early stage. However, 27.8% of patients with fusion at 2 months postoperatively were reassessed as having nonfusion at 6 months after surgery, a condition considered to be fake union. Hence, careful follow-up remains necessary even with apparent early postoperative bony union. Since postoperative weekly teriparatide significantly reduced the rate of fake union and was significantly associated with bony union at 6 months, the drug may be advisable for improving surgical outcomes.

Conflicts of Interest: The authors declare that there are no relevant conflicts of interest.

Sources of Funding: Funding was provided by the Asahi Kasei Pharma Corporation.

Acknowledgement: The authors thank Shigeto Ebata, Keijiro Mukaiyama, Koji Fujita, Yu Yamato, Shou Kobayashi, Daisuke Togawa, Shin Oe, Tatsuya Yasuda, Tsuyoshi Oishi, and Tomohiro Banno, Masayuki Shimizu, Hiroyuki Hashidate, and Nobuhide Ogihara for valuable discussions and their critical review.

Author Contributions: Hiroki Oba wrote and prepared the manuscript, and all of the authors participated in the study design. All authors have read, reviewed, and approved the article.

Ethical Approval: This multicenter study was approved by our institutional review board and registered with the University Hospital Medical Information Network (UMIN) clinical trials registry (UMIN000007151).

References

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
2. Ebata S, Takahashi J, Hasegawa T, et al. Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am. 2017;99(5):365-72.
3. Kleinstuck FS, Grob D, Lattig F, et al. The influence of preoperative back pain on the outcome of lumbar decompression surgery. Spine. 2009;34(11):1198-203.
4. Pearson A, Blood E, Larie J, et al. Predominant leg pain is associated with better surgical outcomes in degenerative spondylolisthesis and spinal stenosis: results from the spine patient outcomes research trial (SPORT). Spine. 2011;36(3):219-29.
5. Lee KB, Tagahi CE, Hsu MS, et al. The efficacy of rhBMP-2 versus autograft for posterolateral lumbar spine fusion in elderly patients. Eur Spine J. 2010;19(6):924-30.
6. Owens RK, 2nd, Djurasovic M, Crawford CH, 3rd, et al. Impact of surgical approach on clinical outcomes in the treatment of lumbar pseudarthrosis. Global Spine J. 2016;6(8):786-91.
7. Flynn JC, Hoque MA. Anterior fusion of the lumbar spine. End-result study with long-term follow-up. J Bone Joint Surg Am. 1979;61(8):1143-50.
8. Lauerman WC, Bradford DS, Ogilvie JW, et al. Results of lumbar pseudarthrosis repair. J Spinal Disord. 1992;5(2):149-57.
9. Waddell G, Kummel EG, Lotto WN, et al. Failed lumbar disc surgery and repeat surgery following industrial injuries. J Bone Joint Surg Am. 1979;61(2):201-7.
10. West JL, 3rd, Bradford DS, Ogilvie JW. Results of spinal arthrodesis with pedicle screw-plate fixation. J Bone Joint Surg Am. 1991;73(8):1179-84.
11. Bridwell KH, Lenke LG, McEnery KW, et al. Anterior fresh frozen structural allografts in the thoracic and lumbar spine. Do they work if combined with posterior fusion and instrumentation in adult patients with kyphosis or anterior column defects? Spine. 1995;20(12):1410-8.
12. Cho PG, Ji FY, Shin DA, et al. An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J. 2017;26(3):691-7.
13. Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine. 2012;37(23):E1464-8.
14. Lee CS, Hwang CJ, Lee DH, et al. Fusion rates of instrumented lumbar spinal arthrodesis according to surgical approach: a systematic review of randomized trials. Clin Orthop Surg. 2011;3(1):39-47.

15. Dobbins JT, 3rd, Godfrey DJ. Digital x-ray tomosynthesis: current state of the art and clinical potential. Phys Med Biol. 2003;48(19):R65-106.

16. Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-84.

17. Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071-7.

18. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346:f2360.